The excretion and tissue distribution of [1-14C] 
Introduction
The chlorination of drinking water results in the formation of by-products including trihalomethanes and halogenated acetonitriles. Dihaloacetonitriles have been found in chlorinated drinking water at a concentration of 0.3 to 8.1 ppb (1) . Haloacetonitriles bind to polyadenylic acid without enzymatic activation. They also induce DNA strand breakage in cultured human CCRF-CEM cells (2) . Several haloacetonitriles induced tumors when applied to the skin of SENCAR mice (3) . Therefore, haloacetonitriles possess the potential for carcinogenic activity.
This paper examines the excretion and organ distribution of dichloroacetonitrile (DCAN) after oral administration to rats and mice as a part of the toxicity studies for this compound. We have examined these parameters with DCAN radiolabeled on each of the two carbon atoms. Differences in disposition of these two radiolabeled compounds determine if the molecule is degraded into one-carbon fragments. tAuthor to whom all correspondence and reprint requests should be addressed.
Methods
The [1-14C]DCAN (specific activity 5.0 mCi/mmole) and [2- 14C]DCAN (specific activity 4.04 mCi/mmole) were purchased from New England Nuclear (Boston, MA). These radiolabeled compounds were purified by distillation in a molecular still (Ace Glass Co., Vineland, NJ) before the dosing solutions were prepared. Purity of the compounds was > 98% as measured by reversephase, high-performance liquid chromatography (HPLC) when the dosing solutions were prepared, but slow degradation of the compound occurred after preparation. HPLC conditions included a solvent of 1:1 (v/v)acetonitrile:water on a 10 PI C18 Alltech (Deerfield, IL) column using ultraviolet detection at 195 nm. Unlabeled DCAN purchased from Pfaltz and Bauer (Waterbury, CT) was determined to be > 98% pure by gas liquid chromatography (GLC) using a 30 m OV 1701 capillary column and a flame ionization detector.
Male Fischer 344 rats weighing 170-250 g and male B6C3F1 mice weighing 18-25 g at the time of administration were purchased from Harlan Sprague-Dawley (Walkersville, MD (Table 1) . Analysis of variance comparing the percentage of administered 14C excreted versus the dose level showed that the fecal elimination and carbon dioxide exhalation were significantly greater at the 15 mg/kg dose than at the lower doses. The carbon dioxide exhalation at 2 mg/kg was also greater than the 0.2 mg/kg dose, and the urinary excretion was lower at the 2 mg/kg dose than the other doses.
After 6 days, the tissues retained 19.3% of the dose. bN.S. = not sampled. Blood retained the highest amount (4 to 8%) followed by muscle (4 to 8%), skin (3 to 6%), and liver (2 to 3%) ( Table 2 ). Total recovery of administered 14C in tissues, body fluids, urine, and feces found in this study ranged from 89.1 to 90.4%. [ 
2-14C]DCAN in Rats
At the three dose levels of [2-14C] DCAN, between 71 and 78% of the dose was excreted within 24 hr (Fig. 2) . This percentage had increased to 82 to 86% of the dose at 48 hr when the experiment was terminated. The urine contained 35 to 40% of the 14C after 48 hr. The expired air contained 33 to 34% of the dose with 0.28 to 0.37% of the dose in the organic trap (data not shown) and the remainder as carbon dioxide. Lesser amounts were found in feces (10 to 13%). Analysis of variance comparing the percentage of administered 14C excreted versus the dose level showed no significant differences in excretion among these doses. After 2 days, the tissues retained 12 to 17% of the dose. Liver retained the highest amount (5.2 to 5.7%) followed by muscle (3 to 5%), blood (2 to 5%) and skin aValues are expressed as percentage of administered dose, x + SD, n = 3. Recovery includes radioactivity from tissues and all excreta.
(1 to 2%) ( Table 3 ). Total recovery of administered 14C in tissue, body fluids, urine, and feces found in this study ranged from 94 to 103%. [ 
1-14C]DCAN in Mice
The excretion of [1-14C]DCAN was substantially more rapid in B6C3F1 mice than in F-344 rats. At the 15 and 2.0 mg/kg dose levels tested, 84.6 and 82.5%, respectively, of the dose were eliminated by 24 hr. The urine contained 69.7% of the 15 mg/kg dose and 63.5% of the 2 mg/kg dose, and the feces contained 9.1 and 13.1%, respectively (Fig. 3) . Only 0.43% of the 15 mg/ kg dose and 0.31% of the 2 mg/kg dose were expired as organics, whereas at these doses, 5.3 to 5.6% was expired as CO2. Statistical tests comparing the percentage of administered 14C excreted versus the dose level showed an increased fecal elimination at the lower dose. After 24 hr, the tissues contained 11 to 12% of the dose. The liver had the highest amount of radioactivity (3.5 to 4.2% of the dose) followed by almost equal amounts in muscle and skin (1.6 to 2.1%) and in blood of the dose) with smaller amounts found in muscle (0.8 to 1.0%), kidney (0.5 to 0.6%), and skin (0.45 to 0.52%) ( Table 5 ). All other tissues contained less than 0.5% of the dose. Total recovery was 92.9% for the 15 mg/kg dose and 96.6% for the 2 mg/kg dose.
Discussion
The use of DCAN radiolabeled at the two different carbon atoms allowed us to determine if the molecule was degraded into one-carbon fragments. Substantial differences in the rate and route of excretion of [1- 14C]DCAN, labeled on the cyanide (CN) group compared to [2-14C]DCAN, labeled on the dichloromethyl group, were found in rats. In mice, the major differences between these labeled compounds were in the route of excretion.
After oral administration, DCAN was rapidly absorbed in rats and mice. If all the radioactivity that appeared in the feces was unabsorbed material, then absorption would be estimated at approximately 90% of the dose. Since bilary excretion may account for some DCAN or its metabolites found in feces, absorption may be greater than 90%. Statistically significant differences in fecal elimination were found when the different doses of [1-14C]DCAN were compared, but they were not observed for [2-14C]DCAN. These fecal elimination differences cannot reflect absorption limitations, as both labeled compounds would act in a similar manner and must reflect differences in metabolism or elimination. The disposition and excretion of [1-14C]DCAN was similar to results from studies on the disposition of cyanide. Cyanide administered intravenously to rats formed about 8% 14CO2 in 7 days (7). The major route of excretion after cyanide administration was the urine; in 24 hr, 45% of the radiolabeled dose was excreted in the urine and this percentage increased to 68% at 7 days. Our studies showed a 24-hr urinary excretion of 28 to 31% in rats and 38 to 44% of the radiolabeled dose in mice. A total of 42 to 45% of the dose appeared in the urine by 6 days in rats. The feces contained 14% of the dose by 7 days in the cyanide studies compared to 14 to 20% in 6 days in our studies. Major tissues containing radioactivity after cyanide dosing were blood (values not given), gastrointestinal tract (4.1%), muscle (1.8%), and liver (0.6%). Blood, muscle, and liver had the highest radioactivity levels after administration of [1- 14C]DCAN. The gastrointestinal tract levels were only 1 to 2% for DCAN and were less than those found for cyanide. Cyanide appeared to concentrate in the gastrointestinal tract after being trapped in the stomach.
After administration of [14C]cyanide, radioactivity was found in several endogenous compounds including choline, methionine, allantoin, and fatty acids (8) . The cyanide carbon probably entered the one-carbon pool through formation of the formate ion, and a slow elimination of radioactivity occurred after the first few days. These findings are consistent with the slow elimination of [1-14C]DCAN in rats. Another indication that cyanide was formed from DCAN was the increased urinary thiocyanite levels found by Pereira and coworkers (6) after administering DCAN to rats.
The metabolism of [2-14C]DCAN would result in the formation of radiolabeled phosgene in a manner analogous to chloroform. Chloroform is metabolized to phosgene, and this reactive intermediate reacts with proteins and amino acids or is further degraded to CO2 (9, 10) . The recoveries in exereta of chloroform and [2- 14C]DCAN are difficult to compare since the predominant route of chloroform elimination is exhalation of unchanged compound. The total amount of 14CO2 collected after oral [14C]chloroform administration of 60 mg/kg to rats was 66%, and the amount of '4C excreted in the urine and feces was 7.6% (11) . Approximately equal amounts of radioactivity were found in CO2 and in urine after oral administration of [2-14C]DCAN in rats and mice. These differences between chloroform and DCAN may be caused by the presence of other metabolic routes for DCAN. Protein binding of 14C to liver was found both after [14C]chloroform administration (9) and after [14C]DCAN administration (2).
The differences in excretion rates between rats and mice may result from a higher rate of metabolism in the mouse for compounds such as chloroform (11) or from different routes of metabolism. Urinary metabolites must be identified before these possibilities can be distinguished.
Some dose-related differences in excretion were noted in these studies. These differences were particularly notable for the CO2 exhalation in rats administered [1-14C]DCAN and for fecal elimination and carbon dioxide exhalation in mice administered [2-14C] DCAN.
Since these differences were not seen for DCAN labeled on the other carbon atom in the same species, the effects probably did not result from the absorption or metabolism of DCAN. Rather, they resulted from metabolism or excretion of the metabolic products and wili require metabolite identification for interpretation.
In summary, DCAN was rapidly absorbed in rats and mice after oral administration. Differences in the route of excretion of [1-14C]-and [2-14C]DCAN indicated that the molecule was cleaved in the body and that the major differences were in the extent of CO2 formation. Mice excreted both labeled compounds by the same routes as rats, but the rate of excretion was much more rapid. Distribution after > 70% of the radioactivity had been excreted showed that the liver contained the highest amount of the dose except in the study of in rats in which the highest levels of the dose were found in the blood.
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